DeepMed Research

Cancer Research UK

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 2002-01-01

Employees: 1K

Market Cap: -

Website: http://www.cancerresearchuk.org

Clinical Trials

A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma

Phase 1

Completed

Conditions: Metastatic Neuroblastoma

Interventions: Drug: [124I]meta-Iodobenzylguanidine

First Posted Date: 2014-01-23

Last Posted Date: 2021-06-21

Lead Sponsor: Cancer Research UK

Target Recruit Count: 36

Registration Number: NCT02043899

Locations: 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧
Royal Marsden Hospital, Sutton, United Kingdom

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

Phase 1

Completed

Conditions: Waldenström Macroglobulinaemia
Chronic Lymphocytic Leukaemia
Indolent B-cell Lymphoma

First Posted Date: 2013-03-06

Last Posted Date: 2018-02-05

Lead Sponsor: Cancer Research UK

Target Recruit Count: 28

Registration Number: NCT01805375

Locations: 🇬🇧
Derriford Hospital, Plymouth, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

and more 2 locations

A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Nasopharyngeal Cancer
Epstein Barr Virus Infections

First Posted Date: 2013-02-27

Last Posted Date: 2018-07-17

Lead Sponsor: Cancer Research UK

Target Recruit Count: 22

Registration Number: NCT01800071

Locations: 🇬🇧
University of Birmingham, Edgbaston, Birmingham, United Kingdom
🇬🇧
Royal Marsden Hospital, Fulham Road, London, United Kingdom
🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom

and more 2 locations

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Adult Solid Tumor
Diffuse Large B Cell Lymphoma
Burkitt Lymphoma

Interventions: Drug: AZD3965

First Posted Date: 2013-02-15

Last Posted Date: 2022-04-11

Lead Sponsor: Cancer Research UK

Target Recruit Count: 53

Registration Number: NCT01791595

Locations: 🇬🇧
The Beatson West of Scotland, Glasgow, Glasgow, United Kingdom
🇬🇧
Royal Marsden Hospital, Sutton, London, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom

and more 4 locations

A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours

Phase 1

Terminated

Conditions: Advanced Solid Tumours

First Posted Date: 2012-08-20

Last Posted Date: 2018-02-05

Lead Sponsor: Cancer Research UK

Target Recruit Count: 43

Registration Number: NCT01668550

Locations: 🇬🇧
Belfast City Hospital, Belfast, United Kingdom
🇬🇧
Edinburgh Cancer Centre - Western General Hospital, Edinburgh, United Kingdom
🇬🇧
Oxford University Hospitals NHS Trust, Oxford, United Kingdom

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer
Cancer

Interventions: Drug: Vandetanib, Selumetinib

First Posted Date: 2012-04-27

Last Posted Date: 2021-10-07

Lead Sponsor: Cancer Research UK

Target Recruit Count: 61

Registration Number: NCT01586624

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧
Churchill Hospital, Headington, Oxford, United Kingdom
🇬🇧
The Christie Hospital, Manchester, United Kingdom

and more 1 locations

Phase I Study of AT13148, a Novel AGC Kinase Inhibitor

Phase 1

Completed

Conditions: Advanced Solid Tumours

First Posted Date: 2012-04-26

Last Posted Date: 2018-07-20

Lead Sponsor: Cancer Research UK

Target Recruit Count: 56

Registration Number: NCT01585701

Locations: 🇬🇧
Royal Marsden Hospital, Institute of Cancer Research, Sutton, Surrey, United Kingdom

A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment

Phase 1

Completed

Conditions: Non-Hodgkin
B-Cell
Lymphoma
Neoplasms
Cancer

First Posted Date: 2012-03-23

Last Posted Date: 2014-12-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 29

Registration Number: NCT01561911

Locations: 🇬🇧
Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, United Kingdom
🇬🇧
Cancer Research UK Medical Oncology Unit, Southampton General Hospital, Tremona Road,, Southampton, United Kingdom

AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2011-09-09

Last Posted Date: 2014-12-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 7

Registration Number: NCT01431664

Locations: 🇬🇧
Royal Marsden Hospital, Surrey, London, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham,, United Kingdom
🇬🇧
Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

and more 2 locations

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2011-07-11

Last Posted Date: 2018-02-05

Lead Sponsor: Cancer Research UK

Target Recruit Count: 34

Registration Number: NCT01390571

Locations: 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧
Royal Marsden Hospital, Sutton, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy